PDS Biotechnology Corpora... (PDSB)
NASDAQ: PDSB
· Real-Time Price · USD
1.22
-0.08 (-6.15%)
At close: Sep 04, 2025, 3:59 PM
1.24
1.64%
Pre-market: Sep 05, 2025, 08:02 AM EDT
-6.15% (1D)
| Bid | 1.16 |
| Market Cap | 56.89M |
| Revenue (ttm) | 59.07K |
| Net Income (ttm) | -36.6M |
| EPS (ttm) | -0.91 |
| PE Ratio (ttm) | -1.34 |
| Forward PE | -1.78 |
| Analyst | Buy |
| Ask | 1.27 |
| Volume | 584,572 |
| Avg. Volume (20D) | 509,716 |
| Open | 1.28 |
| Previous Close | 1.30 |
| Day's Range | 1.16 - 1.30 |
| 52-Week Range | 0.85 - 4.29 |
| Beta | 1.15 |
About PDSB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PDSB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PDSB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
+9.24%
PDS Biotechnology shares are trading higher after ...
Unlock content with
Pro Subscription
3 months ago
-0.63%
PDS Biotechnology shares are trading higher after the company announced phase 2 versamune HPV with pembrolizumab shows median overall survival of 39.3 months in CPS ≥20 patients with recurrent/metastatic HPV16-positive head and neck cancer.
